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Aims The rapidly increasing number of patients with implantable cardioverter-defibrillators (ICD) places a large burden on
follow-up providers. This study investigated the possibility of longer in-office follow-up intervals in primary prevention
ICD patients under remote monitoring with automatic daily data transmissions from the implant memory.
Methods
and results
Conducted in 155 ICD recipients with MADIT II indications, the study compared the burden of scheduled and unsched-
uled ICD follow-up visits, quality of life (SF-36), and clinical outcomes in patients randomized to either 3- or 12-month
follow-up intervals in the periodbetween3and27months after implantation. Remotemonitoring (BiotronikHomeMon-
itoring)wasusedequally in all patients. In contrast toprevious clinical studies, nocalendar-basedremotedatacheckswere
performed between scheduled in-office visits. Compared with the 3-month follow-up interval, the 12-month interval
resulted in a minor increase in the number of unscheduled follow-ups (0.64 vs. 0.27 per patient-year; P ¼ 0.03) and in
a major reduction in the total number of in-office ICD follow-ups (1.60 vs. 3.85 per patient-year; P, 0.001). No signifi-
cant differencewas found in mortality, hospitalization rate, or hospitalization length during the 2-year observation period,
but more patients were lost to follow-up in the 12-month group (10 vs. 3; P ¼ 0.04). The SF-36 scores favoured the
12-month intervals in the domains ‘social functioning’ and ‘mental health’.
Conclusion In prophylactic ICD recipients under automatic daily remote monitoring, the extension of the 3-month in-office follow-
up interval to 12 months appeared to safely reduce the ICD follow-up burden during 27 months after implantation.
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Introduction
Most patients receiving an implantable cardioverter-defibrillator
(ICD) for a primary prevention indication have a low rate of events
necessitating visits to the ICD clinic.1,2 However, regular follow-up
is still considered important to monitor ICD function and the
patient’s condition. Expert consensus advocates clinical checks
every 3–6 months, with an increased frequency in response to
product advisories.3 Alternatively, ICD function and medical events
recorded by the implant can be analysed using remote monitoring
technology.3– 6 Two large randomized clinical trials have shown
that the replacement of regular clinic visits with remote data
checks results in a faster reaction after events requiring intervention
in parallel with a reduced number of in-hospital follow-up examina-
tions.7,8 Inboth trials, longer in-hospital follow-up intervals combined
with remote monitoring were compared with standard follow-up
intervals without remote monitoring.7,8
Because remote monitoring is about to become the standard of
care, it would be of interest to compare longer (e.g. yearly) and stand-
ard in-hospital follow-up intervals in patients undergoing the same
kind of remote monitoring in both study arms in order to assess
the isolated effect of less frequent in-hospital follow-up. Further-
more, the necessity of calendar-based remote follow-up sessions in
the form used in the aforementioned trials7,8 can be questioned for
remote systems capable of automatic physician alerting to relevant
medical and technical events.
The REFORM trial randomized patients receiving prophylactic
ICD treatment for MADIT II indications to either yearly or quarterly
clinic visits. All patients were equally monitored using a remote mon-
itoring system with fully automatic daily transmission and physician
alerting after predefined events. The ICD follow-up burden (sched-
uled and unscheduled clinic visits), generic quality of life (QoL), and
clinical outcomes were compared.
Methods
The Remote Follow-Up for ICD-Therapy in Patients Meeting MADIT II
Criteria (REFORM) study was a randomized, non-blinded, parallel-design
trial, in which three German and two Czech medical centres participated.
The study was conducted in accordance with the Declaration of Helsinki.
Theprotocolwasapprovedby the EthicsCommitteesof theparticipating
institutions. All patients gave their written informed consent to partici-
pate in the trial.
Patient selection
To be enrolled, patients had to meet the MADIT II trial enrolment
criteria; that is, to be survivors of a myocardial infarction and to have a
left-ventricular ejection fraction of ,30%.9 The exclusion criteria were
myocardial infarction within 30 days before enrolment, New York
Heart Association functional class IV, a secondary prevention indication
for ICD therapy, or living in an area lacking the GSM mobile phone cover-
age needed for remote monitoring transmission. Patients indicated for
cardiac pacing were excluded for safety concerns because the ICDs
used in this trial did not have the capability to automatically measure
the pacing threshold. Furthermore, patients indicated for cardiac resyn-
chronization therapy (CRT) according to clinically accepted criteria at
the time of enrolment were not included because the required remote
monitoring system was not available for devices providing CRT.
Remote monitoring
The ICDs used were equipped with the Home Monitoring (HM) capabil-
ity (Biotronik, Berlin, Germany) described previously.5,6,10 –15 Briefly, the
implant transmits dataonceper day, comprising counts of arrhythmia epi-
sodes and therapies, rhythm information, and technical parameters.
Transmission of intracardiac electrograms was available in only a few
devices used in this study. The message sent by the implant is relayed
by the patient device to the HM Service Center (HMSC) via the mobile
phone network. The HMSC makes the data available to the treating phys-
ician on a secure internet site, and also sends alerts by e-mail or SMS if the
data meet user-defined criteria. For long-term performance, HM was
designed to require the patient only to switch on the patient device
and keep it by the bedside. Transmission performance is calculated as
the number of days with data transmission divided by the total number
of days since the first message.
Study protocol
Patients were evenly randomized to quarterly clinic visits (Q-group) or
yearly clinic visits (Y-group). After implantation of a single- or dual-
chamber ICD (Belosw, Lexosw, or Lumosw; Biotronik, Berlin,
Germany), patients in both study arms received the HM patient device.
They were under continuous, automatic remote monitoring during the
entire study. The response to HM alerts was left to the investigators’ dis-
cretion.No calendar-based remote datachecks or remote follow-up ses-
sions were scheduled. All treatments up to the 3-month follow-up were
done according to institutional standards and were equal in both study
arms (Figure 1).
At the 3-month follow-up, all patients’ ventricular function was
re-evaluated. An improved left-ventricular ejection fraction (≥30%) or
the development of a permanent pacing indication was ground for exclu-
sion from the trial. The devices were programmed as follows: ventricular
demand pacing with 40 beats per min (bpm); ventricular tachycardia
zone from 180 bpm with anti-tachycardia pacing therapy; ventricular fib-
rillation zone from 200 bpm with shock therapy; stability and sudden
onset criteria for arrhythmia discrimination ‘ON’. This programming
was subject to adjustments after the occurrence of a first event.
Patients were followed for 2 years after the 3-month follow-up. They
were instructed to refer to the investigational site for ICD-related issues
and heart rhythm disorders. Care for the patients’ concomitant diseases,
most prominently heart failure, was provided by specialists as clinically
indicated; however, they had no role in the study. Study data were
Figure 1 Clinical follow-up schedule. Full circles indicate the
phase affected by patient randomization to quarterly (Q-group)
or yearly (Y-group) routine in-office ICD follow-ups. For the
whole duration of the study, all patients were under automatic,
daily Home Monitoring surveillance, without calendar-based
remote follow-up sessions. ICD, implantable cardioverter-
defibrillator.
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collected by staff dedicated to the trial under the direct supervision of the
principal investigators. Data management was provided by the sponsor.
Data processing was supervised by the clinical team of the first author.
Scheduled follow-up visits
Patients assigned to the Q-group were scheduled to return foroutpatient
visits every3 months, and those assigned to the Y-group had visits at 3, 15,
and 27 months after discharge (Figure 1). A follow-up examination was
classified as regular if occurring within a window of 4 weeks before or
after an appropriate date relative to the discharge date. At each out-
patient visit, the ICD was interrogated and tested and its memory was
analysed in order to adapt patient management accordingly. The
generic health-related QoL was assessed by the 36-item General
Health Survey (SF-36) questionnaire at baseline, 15-month follow-up,
and 27-month follow-up, in both study arms.
Unscheduled follow-up visits
Patients were seen outside of the scheduled visits for the following pre-
specified HM alerts: (i) elective battery replacement indicator; (ii) any
lead impedance out of range; (iii) delivery of a first shock after discharge
of the patient from the hospital; (iv) delivery of ≥5 episodes of anti-
tachycardia pacing; (v) delivery of ≥2 shocks per month for the first
time, or occurrence of ≥2 supraventricular tachycardia or VT episodes
per week. Patients could also be seen at unscheduled visits due to HM
trend data or for any other reason, upon the patient’s request or initiated
by the investigator. Scheduled and unscheduled follow-up examinations
were conducted similarly.
To get an estimate of additional patient contacts to medical profes-
sionals, the patients were instructed to notify such visits in a diary and
were interviewed at each ICD follow-up.
Study hypothesis and endpoints
The primary study hypothesis was that the rate of unscheduled ICD
follow-up visits in the Y-group would exceed the rate in the Q-group
by,1.0 per patient-year, after the 3-month follow-up point. A confirm-
ation of this non-inferiority hypothesis would mean that the total rate of
scheduled and unscheduled ICD follow-up visits would be substantially
lower in the Y-group than in the Q-group.
Secondary endpoints were the intra-individual difference in QoL
scores between 27 months and baseline, total and cardiovascular mortal-
ity, and the rate and duration of all hospitalizations and cardiovascular
hospitalizations. Furthermore, we made a post-hoc analysis of all available
arrhythmia and therapy data (12 different items) extracted from the
HMSC database. The data comprised, per study group, the numbers of
patients fulfilling various criteria such as having episodes in different ar-
rhythmia zones, started or delivered therapies, or unsuccessful
maximum-energy shocks. The underlying arrhythmias in this analysis
were not adjudicated by the investigator. Shock therapy was considered
ineffective if the device delivered more than one shock during one ar-
rhythmia episode, and this could include cases of repeated shocks in epi-
sodes of supraventricular tachycardia.
Statistical analysis
The sample size was based on the primary study hypothesis and calcu-
lated on a Blackwelder-type test of non-inferiority. Unscheduled ICD
follow-up visits were assumed to occur independently from one other,
to have a daily probability (equivalent to 0.21 or 0.96 visits per patient-
year in the Q-group and the Y-group, respectively), and, hence, to
obey binomial distribution. Assuming a 2-year attrition rate of 28% in
both groups, a sample of 150 patients needed to remain in the study
after the 3-month follow-up (for 1-ß ¼ 80%).
All patients with baseline QoL data were included in the intention-
to-treatbased QoL analysis. Missing27-month QoL datawere accounted
for using the last-observation-carried-forward (LOCF) method. Due to
slight post-implantation increase in patients’ QoL and greater loss to
follow-up in the Y-group, this approach can be considered conservative.
For normally distributed continuous data (verified using the Shapiro–
Wilk test), mean values and standarddeviations werecalculated. Fornon-
normally distributed data, median values, interquartile ranges (IQR), and
mean values, if appropriate for comparison with reference data, are
shown. For categorical data, the absolute and relative frequencies were
calculated. Continuous data were compared using the t-test (if normally
distributed) or the Wilcoxon–Mann–Whitney rank test (if non-
normally distributed). Categorical data were compared with a x2 test
according to Pearson’s or Fisher’s exact test as appropriate. One-sided
statistical significance for the primary study hypothesis, or two-sided stat-
istical significance for all other tests, was established as P, 0.05.
Results
Of155patientsenrolled in thestudy, 78wererandomlyassignedtothe
Q-groupand77totheY-group.Thebaselinecharacteristicsof the two
study groups were similar (Table 1). The patients were 63+10 years
old. The meanejection fraction was 25+5%. All patients had a history
of myocardial infarction. As REFORM was planned before publication
of major CRT trials, ventricular dyssynchrony and QRS duration were
not systematically evaluated at enrolment.
At the 3-month follow-up, nine patients (5.8%) were excluded due
to either improved left-ventricular ejection fraction (≥30%) or de-
velopment of a permanent pacing indication (Table 2). Additional
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Table 1 Baseline patient characteristics
Variable All patients
(n5 155)
Q-groupa
(n 5 78)
Y-groupb
(n 5 77)
Mean age+ SD, years 63+10 63+10 63+10
Male gender, % 85.8 88.5 83.1
NYHA 0/I/II/III, % 4/5/49/41 4/4/50/41 5/6/48/41
Median time after MI, months 19 19 19
.6 months, % 73.9 76.6 70.7
.18 months, % 51.1 51.1 51.2
Revascularization before ,3
monthsc
29.9 24.4 33.8
Mean LVEF+ SD, % 25+5 25+6 25+5
Single-/dual-chamber ICD, % 5.8/94.2 5.1/94.9 6.5/93.5
Medication, %
Beta-blocker 89.2 88.0 90.4
ACE-inhibitor or ARB 83.1 80.0 86.3
Diuretic 85.6 82.7 87.7
Anti-arrhythmic 10.8 10.7 11.0
No difference between groups was statistically significant.
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; ICD,
implantable cardioverter-defibrillator; LVEF, left-ventricular ejection fraction; MI,
myocardial infarction; NYHA, New York Heart Association.
aQuarterly vs. byearly scheduled in-office follow-up visits.
cRevascularization within 3 months before enrolment.
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48 patients (31%) terminated the study prematurely due to death,
heart transplantation, pacing system upgrade to biventricular ICD,
or other reasons listed in Table 2, among which only loss to follow-up
differed significantly between the two groups (three in the Q-group
vs. 10 in the Y-group, P ¼ 0.04). The remaining 98 patients (63.2%)
completed the study as planned, at the 27-month follow-up. The
median (IQR) follow-up duration in all 155 patients was 26.6
(14.6–27.5) months; in 57 patients with early study termination,
7.8 (3.5–15.1) months.
One patient assigned to the Y-group preferred to see the physician
more often than once a year. According to the intention-to-treat
principle, he was evaluated within the Y-group, with all clinic visits
other than those at 3, 15, and 27 months classified as unscheduled
patient-initiated follow-ups.
The first HM transmission occurred at 5+ 18 days (median, 1 day)
after patient discharge. Subsequently, HM data were received on
87.1% (83 648 out of 96 066) of all days, including all enrolled
patients. The transmission performance did not differ significantly
between the Q-group (85.0%) and Y-group (89.0%).
Primary study hypothesis
Of145patients (72Q-group, 73Y-group) remaining in the studyafter
the 3-month follow-up, 50 patients (17Q/33Y) had 94 unscheduled
in-office ICD follow-ups (24Q, 70Y) until 27 months. The mean
(median; IQR) number of unscheduled follow-ups per patient-year
was 0.27 (0.00; 0.00–0.35) in the Q-group and 0.64 (0.00; 0.00–
1.00) in the Y-group (P ¼ 0.03). As the increase in the Y-group did
not exceed one additional visit per patient-year (P, 0.001), the
primary study hypothesis was met.
The reasons for 94 unscheduled follow-ups are listed in Table 3.
Nearly two-thirds of unscheduled follow-ups were initiated by
physicians (n ¼ 61; 64.9%) and one-third was initiated by patients
(n ¼ 33; 35.1%).Themost frequently claimedreasonwas ‘arrhythmia
and/or ICD therapy’ (five in the Q-group, 21 in the Y-group). This
marked difference between the two groups can be attributed to a
less need to see the affected patient outside regular follow-up
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Table 2 Reasons for early terminations and the length of follow-up
All patients (n 5 155) Q-groupa (n 5 78) Y-groupb (n5 77)
Exclusion at 3-month follow-up, n 9 6 3
Left-ventricular ejection fraction .30% 8 5 3
Pacing indication 1 1 0
Early termination for other reasons, n 48 22 26
Death 13 7 6
Heart transplantation 2 1 1
Pacing system upgrade to biventricular 6 3 3
Patient withdrawal 7 4 3
Moving away 4 3 1
Lost to follow-up 13 3 10*
Other 3 1 2
Regular termination at 27-month follow-up, n 98 50 48
Median (IQR) follow-up duration, months
All patients (155) 26.6 (14.6–27.5) 26.8 (10.4–27.9) 26.5 (15.6–27.0)
Patients terminating study regularly (98) 27.1 (26.7–27.9) 27.8 (27.0–28.0) 26.8 (26.6–27.2)*
Patients terminating study early (57) 7.8 (3.5–15.1) 5.8 (3.1–10.9) 14.6 (4.0–18.2)*
aQuarterly vs. byearly scheduled in-office follow-up visits.
*P, 0.05. No other difference between groups was significant.
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Table 3 Reasons for unscheduled implantable
cardioverter-defibrillator follow-up visits after the
3-month follow-up
All
patients
Q-groupa Y-groupb
Reason, total number (physician-/patient- initiated)
Arrhythmia or ICD
therapy
26 (11/15) 5 (1/4) 21 (10/11)
Malaise or need for
reassurance
10 (0/10) 1 (0/1) 9 (0/9)
Hospital stay or visits
unrelated to ICD
treatment
15 (14/1) 5 (5/0) 10 (9/1)
Scheduling problem 10 (8/2) 3 (2/1) 7 (6/1)
Implanted device test 2 (0/2) 0 (0/0) 2 (0/2)
Reason not clearly
indicated
31 (28/3) 10 (9/1) 21 (19/2)
Total 94 (61/33) 24 (17/7) 70 (44/26)
ICD, implantable cardioverter-defibrillator.
aQuarterly vs. byearly scheduled in-office follow-up visits.
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schedule in the Q-group, becauseof the relativeproximityof the next
regular visit. Similarly, the number of unscheduled visits caused by
‘patient malaise or need for reassurance’ in susceptible patients
increased directly proportionally to the prolongation of the regular
follow-up interval, with nine such visits in the Y-group and one in
the Q-group. Furthermore, during ‘hospital stay or visits unrelated
to ICD treatment,’ unscheduled follow-ups were undertaken more
frequently in the Y-group (n ¼ 10) than in the Q-group (n ¼ 5),
reflecting a greater likelihood for the physician to check the ICD func-
tion opportunely in a patient who was not supposed to be seen soon
(or was not seen recently) on a regular basis.
The total number of scheduled and unscheduled follow-up visits
after the 3-month follow-up was 421 (Q-group) and 184
(Y-group). The corresponding mean (median; IQR) values per
patient-year were 3.85 (3.90; 3.42–4.15) in the Q-group and 1.60
(1.10; 1.00–2.01) in the Y-group (P, 0.001) (Figure 2). Of note,
the total number of follow-up visits up to and including the
mandatory 3-month follow-up was 144 (Q-group) vs. 146
(Y-group). The cumulative number of unscheduled and total follow-
up visits after device implantation in each group is illustrated in
Figure 3.
Secondary study endpoints and further
analyses
Thirteen patients (8.4%) died during the study (Table 2), all except
two for cardiovascular reasons. Of the 145 patients remaining in
the study after the 3-month follow-up, 70 patients experienced
170 hospitalizations (0.74 per patient-year), lasting for a median
(IQR) of 5 (2–10) days. Cardiovascular reasons caused 68% of the
hospitalizations, lasting for 4 (2–9) days. There were no significant
differences between the study groups in these aspects. Likewise,
the 12 items extracted from the HMSC database did not differ
between the two study arms (all P ≥ 0.4). As shown in Table 4, 50
patients received ICD therapy, 45 had at least one shock charging,
and six had an unsuccessful maximum energy shock.
The SF-36 questionnaire was filled out by 112 patients at baseline,
of which 54 answered the questionnaire also at the 27-month follow-
up, and 23 answered it at the 15-month but not the 27-month follow-
up. Evaluated according to the LOCF method, the mean
intra-individual changes in different SF-36 domains from baseline to
27 months are shown in Figure 4. A significant difference was found
in the domains ‘social functioning’ and ‘mental health,’ in favour of
the Y-group.
Patients from the Q-group reported 1005 additional visits to
medical professionals after the 3-month follow-up, and patients
from the Y-group 942 visits. Neither the percentage of patients
reporting such visits (75% in the Q-group vs. 65% in the Y-group, in-
cluding those who terminated the study prematurely) nor the
number of visits per patient (median 7.7 vs. 7.9, respectively) differed
statistically significantly between the two groups.
Figure 2 The mean numbers of FUs per patient-year after the
3-month follow-up. ICD, implantable cardioverter-defibrillator;
FU, in-office ICD follow-up; Q-group, quarterly routine FU;
Y-group, yearly routine FU. All patients were under close Home
Monitoring surveillance.
Figure3 Cumulative number of unscheduled and total follow-up visits from post-implant discharge up to and including 27-month follow-up. Even
if not required by study protocol, 1-month follow-up was performed in most patents and is categorized as unscheduled follow-up; it had no influence
on study endpoints, for it occurred before the active study period. Unsched., unscheduled; other abbreviations as in Figure 2.
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Loss to follow-up
Of the 10 patients lost to follow-up in the Y-group, four had HM data
transmissions up to 27 months after implantation (they did not die),
one patient was lost at day 5, before any methodological difference
took place between the two groups (Figure 1), and five patients
were lost at 3, 7, 8, 10, and 24 months after implantation. In
these five patients, and in the three patients in the Q-group who
were lost to follow-up at 3, 16, and 17 months, death cannot
be excluded. Even if all these uncertain patients had died, the
mortality in both groups would have remained similar (10-Q vs.
11-Y; P ¼ 0.80).
Discussion
Main findings
In remotely monitored patients with primary prevention ICDs and no
cardiac pacing indications, scheduling yearly instead of quarterly
follow-up visits resulted in 0.37 more unscheduled follow-up visits
per patient-year. However, the total rate of follow-up visits was
reduced by 58% from 3.85 to 1.60 per patient-year. A favourable
impactof longer follow-up intervalon the patients’QoLwasobserved,
while no impact onpatient mortality, hospitalization rate, orother clin-
ical outcomes was evident after the 2-year observation period.
Reduction of follow-up burden
Since the completion of the MADIT II trial, primary prevention of
sudden cardiac death has become the major indication for ICD im-
plantation. The resulting proliferation of ICDs and the parallel intro-
duction of CRT have createda new challenge for individual caregivers
and the healthcare system. The simplest solution, in-office follow-up
interval lengthening, may delay the detection of potentially important
medical events and device failures,16– 20 and is therefore not accept-
able without a remote access to the information stored in implanted
devices’ memories.5 –8,21,22
Previously, the TRUST7 and CONNECT8 trials investigated
remote follow-up in ICD recipients. TRUST enrolled a typical con-
temporary ICD population and used the same remote monitoring
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Table 4 Hospitalizations and implantable cardioverter-defibrillator therapy delivery after the 3-month follow-up
All patients (n 5 155) Q-groupa (n5 78) Y-groupb (n5 77)
Patients remaining after the 3-month FU, n 145 72 73
Cumulative FU duration after the 3-month FU, years 229.5 111.6 117.9
Hospitalizations for all causes, n 170 80 90
Patients with hospitalization 70 32 38
Hospitalizations per patient-year 0.74 0.72 0.76
Median (IQR) length of hospital stay, days 5 (2–10) 5 (2–10) 4 (2–9)
Hospitalizations for adverse CV events, n 116 54 62
Patients with CV hospitalization 55 26 29
CV hospitalizations per patient-year 0.51 0.48 0.53
Median (IQR) length of hospital stay, days 4 (2–9) 3 (2–8) 3.5 (2–8)
Patients with ICD therapy delivery, n
Patients receiving any ICD therapy 50 24 26
Patients with charged shock(s) 45 21 24
Patients with unsuccessful maximum energy shocks 6 2 4
No difference between groups was statistically significant.
CV, cardiovascular; FU, follow-up; ICD, implantable cardioverter-defibrillator; IQR, interquartile range.
aQuarterly vs. byearly scheduled in-office follow-up visits.
Figure 4 Mean intra-individual changes in quality-of-life (SF-36)
scores from baseline to 27 months are shown, generated according
to the last-observation-carried-forward method. Grey columns
denote the Q-group (57 patients); black columns, the Y-group (55
patients). A positive column height indicates improved quality of
life at 27 months and a negative height indicates a deterioration. A
statistically significant difference in the heights of the paired white
andblackcolumns is indicatedby theP-value seenabove thecolumns.
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system as REFORM. Replacing follow-up visits at 6, 9, and 12 months
by scheduled checks of remote data in the HM study arm reduced the
number of total in-hospital follow-ups by 45%.7 Even higher reduc-
tion in REFORM (58%) can be attributed to starting the observation
period after the mandatory 3-month follow-up. The numbers of un-
scheduled visits per patient-year were similar in TRUST (0.78, HM
group) and REFORM (0.64, Y-group). In a mixed population of ICD
and CRT patients, the CONNECT trial replaced visits at 3, 6, 9,
and 12 months with remote follow-ups performed using a substan-
tially different technology (Medtronic CareLink).8 The increase in
the number of unscheduled clinic visits in CONNECT (0.29 per
patient-year)8 was, however, similar to that in TRUST (0.28) and
REFORM (0.37).
Quality of life
The term ‘follow-up burden’ is mainly understood as the hospital’s
burden, taxed by limited resources and budgets. The patient,
however, may also perceive follow-up visits as a burden.23 In
REFORM, mental health and social functioning were improved in
the Y-group at 27 months compared to baseline, while they deterio-
rated in theQ-group.The recent literaturemostly relatesQoL in ICD
recipients to the number of ICD shocks. However, the necessity of
frequent follow-up examinations may also require consideration,
since patients undergoing less frequent clinical examinations might
feel less ill and less distracted from their normal lives. REFORM
offers a first indication that most patients have positive attitude to
longer follow-up intervals, although the cohort studied was too
small for final answer. As some patients may not agree with the main-
stream opinion (one patient randomized to the Y-group wanted to
see his physician more often), physicians should carefully discuss
the pros and cons of remote monitoring concepts with patients.24
Safety aspects
The main concern about lengthening follow-up visit intervals is that
patient condition deterioration may remain undetected for a
longer time. Additional physiological sensors are therefore desirable
to mirror patient health status.25 However, in REFORM, no signifi-
cant difference was found between the Y-group and the Q-group
regarding mortality, hospitalization rate, or hospitalization length,
neither for all causes nor for cardiovascular causes. Likewise, the in-
cidence of arrhythmias and therapies, as indicated by a variety of
device counters, did not differ significantly between the two
groups.Thesefindings are in agreement with TRUSTwheremortality
and adverse event rate were equal in both groups. Albeit, patient ex-
clusion criteria were more stringent in REFORM in that patients with
any cardiac pacing indication were excluded; in TRUST, only pace-
maker dependent patients were left out. Also CONNECT identified
no safety issues, but unlike REFORM and TRUST patients,
CONNECT patients were contacted by telephone for remote
follow-ups and had thereby the opportunity to report health-related
issues. Recently, the EVOLVO study showed that remote monitoring
of heart failure patients with ICDs or an ICD for CRT reduces emer-
gency department and urgent in-office visits and, in general, total
healthcare use.26
The REFORM study adds three safety relevant aspects to the
growing evidence favouring longer follow-up intervals in remotely
monitored patients. First, the follow-up period was 27 months, or
1 year longer than that in TRUST and CONNECT. Secondly, we
did not schedule remote data checks in 3-month intervals, but
relied entirely on automatic HM alerts. Our results support the as-
sumption that regular remote data checks are not needed in a suffi-
ciently reliable and frequent automatic alerting system. Thirdly,
both our study groups were under the equal remote surveillance.
One might argue that TRUST and CONNECT only show that the
safety of longer follow-up intervals with remote monitoring is not in-
ferior to standard follow-up intervalswithout remotemonitoring. The
best possible care in theory, however, should combine standard
follow-up intervals with remote monitoring. Yet, REFORM findings
do not support the superiority of this option over 12-month follow-
up intervals.
The only concerning result is that more patients were lost to
follow-up in the Y-group (10 vs. 3; P ¼ 0.04). The administration
staff in follow-up facilities may therefore need to adapt their efforts
in tracking patients with longer follow-up intervals. Based on the in-
formation provided in the last section of Results, however, it is unlike-
ly that the larger loss to follow-up in the Y-group may have hidden a
significant increase in mortality. Moreover, as hospitalizations were
calculated per patient-year, the greater patient attrition in the
Y-group should not have influenced group comparisons importantly
(Table 4). Of note, cumulative follow-up duration was numerically
even longer in the Y-group (117.9 months) than in the Q-group
(111.6 months) (Table 4).
Both TRUST and CONNECT investigated the median time from
clinical event to clinical decision and found remarkable improve-
ments in the remote monitoring arms (,2 days to clinical decision
in TRUST and 4.6 days in CONNECT).7,8 REFORM did not investi-
gate this issue because remote monitoring was equally used in both
study arms, but it corroborated the other two trials in that follow-up
interval lengthening is feasible and that physician can rely on remote
monitoring information to decide on the necessity of an unscheduled
in-office ICD follow-up. As the reimbursement for, and legal aspects
of, remotemonitoring are unsolved in manycountries, a broaderclin-
ical implementation of the concepts proposed in these trials may,
however, be delayed.27
Study limitations
The investigators were aware of the patients’ group assignment when
deciding on the need for unscheduled ICD follow-ups. This could
have introduced abias suchmay be inclination not to initiateunsched-
uled ICD follow-ups for borderline reasons in the Y-group. A blinded
approach, however, was not possible because all patient’s data were
needed to judge on the necessity of an in-office follow-up. Likewise,
the QoL results could have been affected by the patient’s knowledge
of group assignment.
Our analysis was restricted to ICD-related visits because the
follow-up burden at ICD and CRT follow-up clinics has been increas-
ing exponentially. Although we also assessed the number of patient
contacts to other physicians (for concomitant diseases) based on
patient diary and on interviews at each ICD follow-up, these data
might have been biased towards less contacts reported in the
Y-group because patients may have more difficulty in remembering
all contacts since 12 months than since 3 months ago. The total eco-
nomic effect of our follow-up concept will need to be investigated.
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More than one-third of the enrolled patients did not reach the
regular end of the study. The drop-out rate was only slightly higher
than expected and was reasonably balanced between study groups,
eventually not affecting the evaluation of primary study hypothesis
that reached statistical significance. On the other hand, a larger
study cohort would have enhanced the accuracy of secondary end-
points evaluation. In addition, only half of the enrolled patients con-
tributed to the QoL analysis; the rest of patients did not fill out the
QoL questionnaire either at baseline or at a later time-point.
REFORM results are not transferrable to patients receiving ICDs
for secondary prevention or an ICD for CRT, who potentially have
different needs for remote monitoring and for in-office follow-up
visits. The follow-up duration of 27 months was insufficient to evalu-
ate the results towards the end of the device’s life cycle, when the risk
of failures increases.
Conclusion
In prophylactic ICD recipients without cardiac pacing indications and
under automatic daily remote monitoring, the extension of the
3-month follow-up interval to 12 months appeared to safely
reduce the ICD follow-up burden during 27 months after implant-
ation. In contrast to the previous trials, we did not schedule regular
remote data checks but fully relied on automatic HM alerts. The
SF-36 scores favoured the 12-month interval in the domains ‘social
functioning’ and ‘mental health’.
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